Pharming Group (PHAR) Competitors $8.77 +0.26 (+3.06%) As of 04/30/2025 01:22 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. AMRX, RXRX, IBRX, BHVN, TWST, MTSR, VCEL, SDGR, DNLI, and MIRMShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), Biohaven (BHVN), Twist Bioscience (TWST), Metsera (MTSR), Vericel (VCEL), Schrödinger (SDGR), Denali Therapeutics (DNLI), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Amneal Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Biohaven Twist Bioscience Metsera Vericel Schrödinger Denali Therapeutics Mirum Pharmaceuticals Pharming Group (NASDAQ:PHAR) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Which has more risk & volatility, PHAR or AMRX? Pharming Group has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Does the MarketBeat Community favor PHAR or AMRX? Pharming Group received 5 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.74% of users gave Amneal Pharmaceuticals an outperform vote while only 67.65% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformPharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Amneal PharmaceuticalsOutperform Votes1894.74% Underperform Votes15.26% Which has better earnings & valuation, PHAR or AMRX? Pharming Group has higher earnings, but lower revenue than Amneal Pharmaceuticals. Pharming Group is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M2.01-$10.55M-$0.17-51.59Amneal Pharmaceuticals$2.79B0.85-$83.99M-$0.38-20.16 Does the media favor PHAR or AMRX? In the previous week, Pharming Group had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Pharming Group and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.45 beat Pharming Group's score of 1.07 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PHAR or AMRX? Pharming Group presently has a consensus price target of $30.00, suggesting a potential upside of 242.08%. Amneal Pharmaceuticals has a consensus price target of $10.80, suggesting a potential upside of 40.99%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in PHAR or AMRX? 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is PHAR or AMRX more profitable? Pharming Group has a net margin of -6.09% compared to Amneal Pharmaceuticals' net margin of -6.88%. Pharming Group's return on equity of -7.65% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-6.09% -7.65% -3.82% Amneal Pharmaceuticals -6.88%-346.26%4.85% SummaryAmneal Pharmaceuticals beats Pharming Group on 9 of the 17 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$523.17M$6.90B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-33.737.4422.4418.48Price / Sales2.01242.73394.10103.59Price / Cash91.8265.8538.1834.62Price / Book2.696.516.774.25Net Income-$10.55M$143.21M$3.22B$248.23M7 Day Performance6.05%3.95%3.25%3.29%1 Month Performance4.70%0.34%0.01%2.42%1 Year Performance-6.60%2.58%18.00%5.54% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.724 of 5 stars$8.77+3.1%$30.00+242.1%-6.6%$523.17M$297.20M-33.73280Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpAMRXAmneal Pharmaceuticals3.3576 of 5 stars$7.13-3.1%$10.80+51.5%+26.6%$2.21B$2.79B-10.497,600Positive NewsRXRXRecursion Pharmaceuticals2.2202 of 5 stars$5.41-1.6%$8.20+51.6%-28.5%$2.17B$58.49M-3.54400Upcoming EarningsGap DownIBRXImmunityBio1.6292 of 5 stars$2.51+1.6%$12.19+385.6%-68.6%$2.14B$14.75M-2.73590Upcoming EarningsAnalyst ForecastBHVNBiohaven3.6241 of 5 stars$20.67+1.5%$62.77+203.7%-43.0%$2.11BN/A-2.21239Upcoming EarningsAnalyst ForecastGap DownTWSTTwist Bioscience3.6043 of 5 stars$34.56-6.1%$52.80+52.8%+22.7%$2.06B$330.19M-10.22990Upcoming EarningsPositive NewsGap DownMTSRMetseraN/A$19.51-0.3%$47.00+140.9%N/A$2.05BN/A0.0081News CoverageHigh Trading VolumeVCELVericel2.3089 of 5 stars$40.87-0.9%$60.86+48.9%-17.1%$2.05B$237.22M681.28300Upcoming EarningsPositive NewsSDGRSchrödinger2.2806 of 5 stars$26.19+1.7%$33.00+26.0%+5.1%$1.91B$207.54M-11.19790Upcoming EarningsGap DownDNLIDenali Therapeutics4.1332 of 5 stars$13.15+3.2%$37.57+185.7%+7.8%$1.91B$330.53M-4.76430Upcoming EarningsPositive NewsMIRMMirum Pharmaceuticals4.2385 of 5 stars$38.39-1.8%$58.20+51.6%+73.0%$1.90B$336.89M-19.00140Upcoming EarningsPositive News Related Companies and Tools Related Companies AMRX Competitors RXRX Competitors IBRX Competitors BHVN Competitors TWST Competitors MTSR Competitors VCEL Competitors SDGR Competitors DNLI Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAR Stock Free PHAR Stock Alerts